KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Accumulated Expenses (2016 - 2025)

Ionis Pharmaceuticals has reported Accumulated Expenses over the past 17 years, most recently at $116.2 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $116.2 million for Q4 2025, up 66.97% from a year ago — trailing twelve months through Dec 2025 was $116.2 million (up 66.97% YoY), and the annual figure for FY2025 was $116.2 million, up 66.97%.
  • Accumulated Expenses for Q4 2025 was $116.2 million at Ionis Pharmaceuticals, up from $57.0 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for IONS hit a ceiling of $147.9 million in Q4 2023 and a floor of $21.5 million in Q1 2024.
  • Median Accumulated Expenses over the past 5 years was $101.0 million (2022), compared with a mean of $89.1 million.
  • Biggest five-year swings in Accumulated Expenses: crashed 80.89% in 2024 and later surged 377.02% in 2025.
  • Ionis Pharmaceuticals' Accumulated Expenses stood at $38.8 million in 2021, then surged by 260.99% to $140.1 million in 2022, then increased by 5.56% to $147.9 million in 2023, then plummeted by 52.93% to $69.6 million in 2024, then soared by 66.97% to $116.2 million in 2025.
  • The last three reported values for Accumulated Expenses were $116.2 million (Q4 2025), $57.0 million (Q3 2025), and $99.0 million (Q2 2025) per Business Quant data.